Covid-19: How the UK vaccine rollout delivered success, so far

  title={Covid-19: How the UK vaccine rollout delivered success, so far},
  author={Chris Baraniuk},
Chris Baraniuk explains the elements that have made the UK’s vaccination programme a front runner globally and describes the hurdles that lie ahead 

Analysing the Launch of COVID-19 Vaccine National Rollouts: Nine Case Studies

These case studies examine the early stages of COVID-19 vaccine rollouts across nine regions from around the world, using published clinical trials, government documents and news reports as sources of data to learn a great deal about which methods were successful, and in which areas strategies can be improved.

Evidence Review: Achieving COVID-19 Vaccine Equity in Ealing and North West London

This review sets out key considerations for improving vaccine equity – as well as broader health equity – in the North West London (NWL) borough of Ealing. It foregrounds the political, economic and

A look into the future of the COVID-19 pandemic in Europe: an expert consultation

Improving COVID-19 vaccination centre operation through computer modelling and simulation

The value of computer modelling is demonstrated through providing an account of its use in supporting management considerations and decisions at two major vaccination centres, at an early stage of the UK's mass vaccination effort.

Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.

Booster vaccination during Delta variant predominance reduced the health burden of SARS-CoV-2 in the UK, releasing substantial NHS capacity and saving healthcare resources saved.

Maximisation of open hospital capacity under shortage of SARS-CoV-2 vaccines

A rollout scheme assigning vaccine doses to staff primarily by staff's pathogen exposure maximises the predicted open hospital capacity when compared to a rollout based on hierarchical prioritisation, which increases under resource scarcity and increasing disease activity.

Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America

Vaccine hesitancy, defined as the reluctance or rejection in receiving a vaccine despite its availability, represents a major challenge to global health efforts aiming to control the ongoing

Waning, Boosting and a Path to Endemicity for SARS-CoV-2.

It is found that boosters are necessary to suppress the imminent wave of infections that would be generated by waning vaccine efficacy and to limit subsequent epidemic peaks an reduce the pressure on public health services.


Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval

Taking all this evidence together, the 12 week gap between first and second dose is clearly the better strategy as more people can be protected more quickly and the ultimate protective effect is greater.